Online inquiry

IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3315MR)

This product GTTS-WQ3315MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets lukG&lukH gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_000791407.1; WP_000791411.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59700810; 59700811
UniProt ID A0A390DBJ6; A0A390DBJ6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3315MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12023MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ6504MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ13711MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ4728MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ8996MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ11124MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ15745MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ11857MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW